Kulke Matthew H
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.
Expert Rev Anticancer Ther. 2003 Oct;3(5):729-39. doi: 10.1586/14737140.3.5.729.
Once thought to be a relatively untreatable disease, pancreatic cancer has recently become a focus of intense clinical research. The systemic administration of gemcitabine (Gemzar) is currently considered the standard first-line treatment for patients with advanced disease. While treatment with gemcitabine has been shown to result in both clinical benefit and prolongation of survival, objective tumor responses are relatively uncommon and median survival times remain short. Several recent efforts have therefore focused on evaluating chemotherapy regimens in which gemcitabine is combined with other cytotoxic drugs. While randomized trials have now confirmed that such combinations are associated with higher response rates, they have not yet clearly demonstrated that combination therapy results in a survival advantage. Increasingly, attention has turned to a number of novel chemotherapeutic and biologic agents that appear promising and are likely to play an important future role in the treatment of patients with this disease.
胰腺癌曾被认为是一种相对难以治疗的疾病，近来已成为临床深入研究的焦点。目前，吉西他滨（健择）的全身给药被视为晚期胰腺癌患者的标准一线治疗方法。虽然已证明使用吉西他滨治疗可带来临床益处并延长生存期，但客观肿瘤反应相对少见，中位生存时间仍然较短。因此，最近的几项研究致力于评估吉西他滨与其他细胞毒性药物联合使用的化疗方案。虽然随机试验现已证实此类联合用药具有更高的缓解率，但尚未明确表明联合治疗能带来生存优势。越来越多的注意力转向了一些新的化疗和生物制剂，这些药物看起来很有前景，可能会在该病患者的治疗中发挥重要的未来作用。
